Efficacy of sorafenib combined with transarterial chemoembolization in the treatment of advanced hepatocellular carcinoma: A meta-analysis

Table 1 Characteristics of included studies in the meta-analysis and systematic review

Ref.	Year	Number of cases	Mean age (years)	Design	Dose of sorafenib	Chemoembolization agents
Zheng et al[18]	2022	32 vs 32	56 vs 55	RCT	400 mg twice daily	Epirubicin, cisplatin, doxorubicin, mitomycin
He et al[16]	2019	125 vs 122	49 vs 49	RCT	400 mg twice daily	Mitomycin, doxorubicin
Kondo et al[17]	2019	35 vs 33	72 vs 71	RCT	400 mg twice daily	Oxaliplatin, fluorouracil, epirubicin
Zhao et al[20]	2019	46 vs 58	NA	Retrospective cohort study	400 mg twice daily	Oxaliplatin, epirubicin
Kudo et al[22]	2018	102 vs 103	67 vs 68	RCT	400 mg twice daily	Cisplatin, fluorouracil
Ikuta et al[19]	2018	26 vs 72	72 vs 69	Retrospective cohort study	400 mg twice daily	Cisplatin, fluorouracil, lipiodol
Ikeda et al[14]	2016	65 vs 41	66 vs 64	RCT	400 mg twice daily	Cisplatin
Bai et al[24]	2013	82 vs 164	54 vs 52	Prospective nonrandomized study	400 mg twice daily	Mitomycin, doxorubicin
Muhammad et al[25]	2013	13 vs 30	61 vs 59	Retrospective cohort study	200 mg increased to 400 mg	Doxorubicin
Sansonno et al[23]	2012	31 vs 31	73 vs 72.8	RCT	400 mg twice daily	Mitomycin, doxorubicin
Qu et al[21]	2012	45 vs 45	51 vs 49	Retrospective study	400 mg twice daily	Oxaliplatin, fluorouracil, epirubicin
Kudo et al[15]	2011	229 vs 229	69 vs 70	RCT	200 mg twice daily	Epirubicin, cisplatin, doxorubicin, mitomycin

NA: Not available; RCT: Randomized controlled trial.

Table 2 The quality assessment according to Newcastle-Ottawa Scale of each cohort study

Ref.	Selection			Comparability		Outcome			Total score
	Representativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	Assessment of outcome	Was follow-up long enough	Adequacy of follow up of cohorts
Zhao et al[20]		1	1	1	2	1	1	1	8
Ikuta et al[19]	1	1	1	1	2	1	1	1	9
Bai et al[24]	1	1	1	1	2	1	1	1	9
Muhammad et al[25]	1	1	1	1	1	1	1	1	8
Qu et al[21]	1	1	1	1	1	1	1	1	8